Utility of chemoradioselection for the optimization of treatment intensity in advanced hypopharyngeal and laryngeal carcinoma

Masuda,Muneyuki; Wakasaki,Takahiro; Toh,Satoshi; Uchida,Yoshinori; Rikimaru,Hidefumi; Kunitake,Naonobu; Higaki,Yuichiro

doi:10.3892/mco.2017.1466

Utility of chemoradioselection for the optimization of treatment intensity in advanced hypopharyngeal and laryngeal carcinoma

Authors:
- Muneyuki Masuda
- Takahiro Wakasaki
- Satoshi Toh
- Yoshinori Uchida
- Hidefumi Rikimaru
- Naonobu Kunitake
- Yuichiro Higaki
View Affiliations

Affiliations: Department of Head and Neck Surgery, National Kyushu Cancer Center, Minamiku, Fukuoka 811‑1395, Japan, Department of Radiology, National Kyushu Cancer Center, Minamiku, Fukuoka 811‑1395, Japan
Published online on: October 20, 2017 https://doi.org/10.3892/mco.2017.1466
Pages: 965-970
Copyright: © Masuda et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Definitive concomitant chemoradiotherapy (CRT) with high‑dose cis‑platinum (CDDP) is a current standard protocol for advanced laryngeal and hypopharyngeal cancer sparing surgery for salvage. However, this modality is associated with limited feasibility and frequent sever toxicities. In the present study, a ‘chemoradioselection’ protocol with minimal toxicity was developed using initial response to CRT as a biomarker for patient selection. Between 2000, March and 2012, September 123 patients with stage III (44), IV (79) laryngeal (64) and hypopharyngeal carcinoma (59) excluding T4 cases were enrolled to this protocol. Two cycles of split (15 mg/m2 x5 days, 2000‑2008) or bolus (80 mg/m2, 2009‑present) CDDP was concurrently administered. Tumor responses were evaluated after 40 Gy of CRT and 64 responders (chemoradioselected, CRS) received further CRT up to 70 Gy, while radical surgery was recommended for the 59 non‑responders (N‑CRS), and 34 underwent surgery (N‑CRS‑ope). The remaining 25 patients who refused surgery (N‑CRS‑refu) were treated with continuous CRT. The 5‑year overall survival (OS) and disease‑specific survival (DSS) were 67, and 77%, respectively. The CRS demonstrated favorable 5‑year OS (73%) and laryngo‑esophageal dysfunction‑free survival (LEDFS, 69%) rates. In contrast, the N‑CRS‑refu showed significantly lower 5‑year OS (47%) compared with CRS (73%) and N‑CRS‑ope (70%) (P=0.0193), and significantly lower 5‑year LEDFS (20%) compared with the CRS (69%) (P<0.0001). On multivariate analyses, including T, N, primary site and planned treatment (CRS + N‑CRS‑ope) or not (N‑CRS‑refu), unplanned treatment alone showed a significant correlation with poor OS [hazard ratio (HR), 2.584; 95% confidence interval (CI), 1.313‑4.354; P=0.007). Chemoradioselection reflects the biological aggressiveness of each tumor, and is able to segregate patients for functional laryngeal preservation with moderate intensity CRT (150‑160 mg/m2 of CDDP) from those who would be better treated with surgery. This strategy may be useful for the optimization of the therapeutic intensity.

View Figures

View References

1	Department of Veterans Affairs Laryngeal Cancer Study Group, . Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K and Henderson WG: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 324:1685–1690. 1991. View Article : Google Scholar : PubMed/NCBI
2	Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L and Sahmoud T: Larynx preservation in pyriform sinus cancer: Preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 88:890–899. 1996. View Article : Google Scholar : PubMed/NCBI
3	Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
4	Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
5	Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR and Carroll MA: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. J Clin Oncol. 24:1064–1071. 2006. View Article : Google Scholar : PubMed/NCBI
6	Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003. View Article : Google Scholar : PubMed/NCBI
7	Hanna GJ, Haddad RI and Lorch JH: Induction chemotherapy for locoregionally advanced head and neck cancer: Past, present, future? Oncologist. 18:288–293. 2013. View Article : Google Scholar : PubMed/NCBI
8	Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol. 14:257–264. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A and Robinson RA: Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival. Laryngoscope. 116 9 Pt 2 Suppl 111:S1–S13. 2006. View Article : Google Scholar
10	Newman JR, Connolly TM, Illing EA, Kilgore ML, Locher JL and Carroll WR: Survival trends in hypopharyngeal cancer: A population-based review. Laryngoscope. 125:624–629. 2015. View Article : Google Scholar : PubMed/NCBI
11	Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A and Ang KK: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol. 26:3582–3589. 2008. View Article : Google Scholar : PubMed/NCBI
12	Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B and Vokes EE: Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 10:1956–1962. 2004. View Article : Google Scholar : PubMed/NCBI
13	Corry J, Peters LJ and Rischin D: Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol. 11:287–291. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kumamoto Y, Masuda M, Kuratomi Y, Toh S, Shinokuma A, Chujo K, Yamamoto T and Komiyama S: ‘FAR’ chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Head Neck. 24:637–642. 2002. View Article : Google Scholar : PubMed/NCBI
15	Masuda M, Kamizono K, Uryu H, Fujimura A and Uchi R: Roles of therapeutic selective neck dissection in multidisciplinary treatment. Journal, 2012Neck Dissection - Clinical Application and Recent Advances. In Tech; Croatia: pp. 49–60. 2012
16	Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 5:2000–2005. 1999.PubMed/NCBI
17	Nonoshita T, Shioyama Y, Nakamura K, Nakashima T, Ohga S, Yoshitake T, Ohnishi K, Terashima K and Asai K: Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma. J Radiat Res. 51:481–484. 2010. View Article : Google Scholar : PubMed/NCBI
18	Ohnishi K, Shioyama Y, Nakamura K, Nakashima T, Ohga S, Nonoshita T, Yoshitake T, Terashima K, Komune S and Honda H: Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. J Radiat Res. 52:47–53. 2011. View Article : Google Scholar : PubMed/NCBI
19	Masuda M, Matsuo M, Aso T, Kiyohara H, Rikimaru F, Kunitake N and Higaki Y: Utility of algorithm-based chemoradioselection in the treatment for advanced hypopharyngeal carcinoma. Head Neck. 37:1290–1296. 2015. View Article : Google Scholar : PubMed/NCBI
20	Strojan P, Haigentz M Jr, Bradford CR, Wolf GT, Hartl DM, Langendijk JA, Rinaldo A, Eisbruch A, Mendenhall WM, Forastiere AA, et al: Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. Oral Oncol. 49:283–286. 2013. View Article : Google Scholar : PubMed/NCBI
21	Forastiere AA, Weber RS and Trotti A: Organ preservation for advanced larynx cancer: Issues and outcomes. J Clin Oncol. 33:3262–3268. 2015. View Article : Google Scholar : PubMed/NCBI
22	Lefebvre JL and Ang KK: Larynx Preservation Consensus Panel: Larynx preservation clinical trial design: Key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys. 73:1293–1303. 2009. View Article : Google Scholar : PubMed/NCBI
23	Cohen EE, Karrison TG, Kocherginsky M, Huang CH, Agulnik M, Mittal BB, Yunus F, Samant S, Brockstein B, Raez LE, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 30 suppl:S55002012.
24	Hitt R, Grau JJ, Lopez-Pousa A, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Castelo Brandariz JA, et al: A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 25:216–225. 2014. View Article : Google Scholar : PubMed/NCBI
25	Blanchard P, Landais C, Petit C, et al: Meta-analysis of chemotherapy in head and neck cencer (MACH-NC): an update on 100 randamized traials and 19,248 patients, on behalf of MANH-HN group. ESMO Meeting abstract. 950O:2016
26	Ang KK: Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: Are we addressing burning subjects? J Clin Oncol. 22:4657–4659. 2004. View Article : Google Scholar : PubMed/NCBI
27	Melotek JM, Cooper BT, Koshy M, Silverman JS and Spiotto MT: Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. J Otolaryngol Head Neck Surg. 45:622016. View Article : Google Scholar : PubMed/NCBI
28	Ho KF, Swindell R and Brammer CV: Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol. 47:1513–1518. 2008. View Article : Google Scholar : PubMed/NCBI
29	Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N and Taylor J: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol. 24:593–598. 2006. View Article : Google Scholar : PubMed/NCBI
30	Aso T, Matsuo M, Kiyohara H, Taguchi K, Rikimaru F, Shimokawa M, Segawa Y, Higaki Y, Umeno H, Nakashima T and Masuda M: Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer. PLoS One. 10:e01165962015. View Article : Google Scholar : PubMed/NCBI